Cargando…

Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer

BACKGROUND: This multicenter, randomized phase II trial was conducted to compare the efficacy and safety of nimotuzumab plus irinotecan (N-IRI) versus irinotecan alone (IRI) in patients with advanced gastric cancer (AGC) showing disease progression after previous 5-fluorouracil-based therapy. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Satoh, Taroh, Lee, Kyung Hee, Rha, Sun Young, Sasaki, Yasutsuna, Park, Se Hoon, Komatsu, Yoshito, Yasui, Hirofumi, Kim, Tae-You, Yamaguchi, Kensei, Fuse, Nozomu, Yamada, Yasuhide, Ura, Takashi, Kim, Si-Young, Munakata, Masaki, Saitoh, Soh, Nishio, Kazuto, Morita, Satoshi, Yamamoto, Eriko, Zhang, Qingwei, Kim, Jung-mi, Kim, Yeul Hong, Sakata, Yuh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Japan 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4572054/ https://www.ncbi.nlm.nih.gov/pubmed/25185971 http://dx.doi.org/10.1007/s10120-014-0420-9

Ejemplares similares

Irinotecan Monotherapy Versus Irinotecan-Based Combination as Second-Line Chemotherapy in Advanced Gastric Cancer: A Meta-Analysis
por: Cho, Yo-Han, et al.
Publicado: (2017)

Irinotecan-Induced Dysarthria
por: Dressel, Albertine J., et al.
Publicado: (2012)

Microbiota-Host-Irinotecan Axis: A New Insight Toward Irinotecan Chemotherapy
por: Yue, Bei, et al.
Publicado: (2021)

Irinotecan-gut microbiota interactions and the capability of probiotics to mitigate Irinotecan-associated toxicity
por: Mahdy, Marwa S., et al.
Publicado: (2023)

Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer
por: Adiwijaya, BS, et al.
Publicado: (2017)

Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer
por: Doi, Toshihiko, et al.
Publicado: (2015)

Combination chemotherapy consisting of irinotecan, etoposide, and carboplatin for refractory or relapsed neuroblastoma
por: Imaya, Masayuki, et al.
Publicado: (2022)

The novel tankyrase inhibitor (AZ1366) enhances irinotecan activity in tumors that exhibit elevated tankyrase and irinotecan resistance
por: Quackenbush, Kevin S., et al.
Publicado: (2016)

Synergistic Effects of Simvastatin and Irinotecan against Colon Cancer Cells with or without Irinotecan Resistance
por: Jang, Hyun Joo, et al.
Publicado: (2016)

Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancer
por: Doi, Toshihiko, et al.
Publicado: (2013)

Effects of methimazole on the elimination of irinotecan
por: van der Bol, Jessica M., et al.
Publicado: (2010)

Clinical outcomes of liposomal irinotecan plus fluorouracil/leucovorin for metastatic pancreatic adenocarcinoma in patients previously treated with conventional irinotecan-containing chemotherapy
por: Bang, Kyunghye, et al.
Publicado: (2021)

Correlation of UGT1A1 Gene Polymorphisms or Prior Irinotecan Treatment and Treatment Outcomes of Nanoliposomal-Irinotecan plus 5-Fluorouracil/Leucovorin for Pancreatic Ductal Adenocarcinoma: A Multicenter, Retrospective Cohort Study (HGCSG2101)
por: Harada, Kazuaki, et al.
Publicado: (2023)

Irinotecan-containing doublet treatment versus irinotecan monotherapy as second-line choice for advanced gastric cancer
por: Yang, Liuting, et al.
Publicado: (2018)

Prior irinotecan exposure does not preclude benefit to liposomal irinotecan in patients with metastatic pancreatic ductal adenocarcinoma
por: Yu, Kenneth H., et al.
Publicado: (2023)

Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer
por: Chon, Hong Jae, et al.
Publicado: (2011)

Irinotecan toxicity: genes or intestinal microflora?
por: Brandi, G, et al.
Publicado: (2009)

Herbal Medicines for Irinotecan-Induced Diarrhea
por: Tang, Liu, et al.
Publicado: (2019)

Irinotecan-Induced Steatohepatitis: Current Insights
por: Han, Jun, et al.
Publicado: (2021)

Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer
por: Ioka, T, et al.
Publicado: (2017)

The UGT1A9*22 genotype identifies a high-risk group for irinotecan toxicity among gastric cancer patients
por: Lee, Choong-kun, et al.
Publicado: (2022)

Irinotecan-encapsulated double-reverse thermosensitive nanocarrier system for rectal administration
por: Din, Fakhar ud, et al.
Publicado: (2017)

Targeting Mitochondrial Oxidative Phosphorylation Abrogated Irinotecan Resistance in NSCLC
por: Lee, Soohyun, et al.
Publicado: (2018)

Successful Treatment of Small-Cell Lung Cancer With Irinotecan in a Hemodialysis Patient With End-Stage Renal Disease
por: Kim, Dong Min, et al.
Publicado: (2009)

Bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
por: Bang, Yeong Hak, et al.
Publicado: (2021)

Combination therapy with irinotecan and cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer
por: Sugiyama, T, et al.
Publicado: (1999)

Phase II study of docetaxel and irinotecan combination chemotherapy in metastatic gastric carcinoma
por: Park, S R, et al.
Publicado: (2006)

Phase II Study of Irinotecan and Cisplatin Combination Chemotherapy in Metastatic, Unresectable Esophageal Cancer
por: Kim, Miso, et al.
Publicado: (2017)

Oxaliplatin but Not Irinotecan Impairs Posthepatectomy Liver Regeneration in a Murine Model
por: Soriano, Perry A., et al.
Publicado: (2011)

Formulation and Evaluation of Irinotecan Suppository for Rectal Administration
por: Feng, Haiyang, et al.
Publicado: (2014)

Irinotecan-Induced Serpentine Supravenous Hyper-Pigmentation
por: Gaurav, Vishal, et al.
Publicado: (2022)

Irinophore C™, a lipid nanoparticle formulation of irinotecan, abrogates the gastrointestinal effects of irinotecan in a rat model of clinical toxicities
por: Waterhouse, Dawn N., et al.
Publicado: (2014)

Irinotecan Upregulates Fibroblast Growth Factor Receptor 3 Expression in Colorectal Cancer Cells, Which Mitigates Irinotecan-Induced Apoptosis()()
por: Erdem, Zeynep N., et al.
Publicado: (2017)

Soluble HLA-G expression levels and HLA-G/irinotecan association in metastatic colorectal cancer treated with irinotecan-based strategy
por: Scarabel, Lucia, et al.
Publicado: (2020)

Second-Line Irinotecan, Leucovorin, and 5-Fluorouracil for Gastric Cancer Patients after Failed Docetaxel and S-1
por: Jung, Joo Young, et al.
Publicado: (2016)

Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial
por: Seymour, Matthew T, et al.
Publicado: (2013)

A Case of Typhlitis Developed after Chemotherapy with Irinotecan and Cisplatin in a Patient with Small Cell Lung Carcinoma
por: Ji, Eun Hye, et al.
Publicado: (2012)

Phase II Study of Continued Trastuzumab Plus Irinotecan in Patients with HER2-positive Gastric Cancer Previously Treated with Trastuzumab (HGCSG 1201)
por: Kawamoto, Yasuyuki, et al.
Publicado: (2022)

Association of CHFR Promoter Methylation with Treatment Outcomes of Irinotecan-Based Chemotherapy in Metastatic Colorectal Cancer
por: Cha, Yongjun, et al.
Publicado: (2018)

Induction cisplatin–irinotecan followed by concurrent cisplatin–irinotecan and radiotherapy without surgery in oesophageal cancer: multicenter phase II FFCD trial
por: Michel, P, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_uk2usn6srq8t7lv61pbnaohic6